- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02888704
Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atopic dermatitis (AD) is a type of inflammation of the skin. It results in itchy, swollen, red, and cracked skin. The symptoms typically start in childhood with changing severity over the years. The pathogenesis of AD is characterized by excessive type 2 helper T cell mediated inflammatory responses, resulting in B lymphocyte mediated increase in serum level of immunoglobulin E (IgE). Subsequent degranulation of mast cells by IgE releases various inflammatory mediators, which recruit the lymphocytes and eosinophils into the lesion.
Current clinical management of AD includes topical corticosteroids and systemic immunosuppressants. However, these drugs have been reported to carry the risk of side-effects and severe.
Several recent studies including ours have demonstrated that mesenchymal stem cells (MSCs) could suppress allergic responses in AD. MSCs have been known to interact with cell types of both innate and adaptive immune systems, which results in the suppressive effect on proliferation, differentiation, and activation of immune cells including T cells, B cells, dendritic cells, and natural killer cells. Indeed, a number of studies have reported that the immunomodulatory ability of MSCs can be usefully applied for the treatment of autoimmune and inflammation-related diseases such as asthma, rhinitis, and dermatitis. Therefore, MSCs has possibility as a new drug for AD.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Chungcheongnam-do
-
Daejeon, Chungcheongnam-do, Korea, Republic of, 35015
- Chungnam National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Of either gender, aged ≥19 and ≤70 years
- Atopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria
- Subacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months
- Subjects with over moderate atopic dermatitis (SCORAD score > 20)
- Subjects who understand and voluntarily sign an informed consent form
Exclusion Criteria:
- Subjects who have systemic infection
- Subjects who have human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV)
- Subjects who need to take the medicine which is prohibited during this study
- Subjects who have asthma
- Subjects who can not stop treatment with topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the treatment visit
- Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test)
- Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days
- Subjects who had a serious adverse events during stem cell therapy
- Subjects who had a hypersensitivity to antibiotics or antimycotics
- Subjects who creatinine value is more than two times of the upper limit of the normal range at screening test
- Subjects who aspartate transaminase/alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test
- Subjects who have any other condition which the investigator judges would make patients unsuitable for study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intervention: Biological: ADSTEM Inj.
|
Comparison of different dosages of the drug in the aspect of safety and efficacy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03
Time Frame: 12 weeks follow-up after treatment
|
physical exam, vital sign, laboratory findings, and adverse drug reactions
|
12 weeks follow-up after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of SCORAD index as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of each index score of SCORAD index as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
TBSA, erythema, edema/papulation, oozing/crusting, excoriation, lichenification, dryness, pruritus, and insomnia
|
12 weeks follow-up after treatment
|
The variation of the degrees of disease as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of investigator's global assessment (IGA) as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of eczema area and severity index (EASI) total score as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
|
The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value
Time Frame: 12 weeks follow-up after treatment
|
12 weeks follow-up after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Young-joon Seo, M.D., Ph.D, Chungnam National University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-CP-15-1
- 30902 (Other Grant/Funding Number: Republic of Korea Ministry of Food and Durg Safety)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
Clinical Trials on ADSTEM Inj. (Adult human mesenchymal stem cells)
-
Joshua M HareThe Emmes Company, LLCCompletedMyocardial Infarction | Chronic Ischemic Left Ventricular DysfunctionUnited States
-
Mesoblast, Inc.CompletedCrohn's DiseaseUnited States
-
Gangnam Severance HospitalDaewoong Pharmaceutical Co. LTD.CompletedRecessive Dystrophic Epidermolysis BullosaKorea, Republic of
-
Central South UniversityUnknown
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedDiabetes Mellitus, Type 2United States
-
Stemedica Cell Technologies, Inc.University of California, San Diego; Mercy Gilbert Medical Center at AZ; Chandler... and other collaboratorsCompletedIschemic StrokeUnited States
-
Clinica Universidad de Navarra, Universidad de...CompletedIdiopathic Pulmonary FibrosisSpain
-
National Yang Ming UniversityCompleted
-
Shenzhen Beike Bio-Technology Co., Ltd.The Second Affiliated Hospital of Kunming Medical UniversityUnknown
-
Limin RongCompleted